Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | HAT1 | O14929 | 2/20 | 0.32 |
| ▸ | EP300 | Q09472 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930333 | 0.86 | BRAF (0.49) | BRAFTP53CYP2C9 | |
| SCHEMBL9930219 | 0.82 | BRAF (0.48) | BRAFTP53LMNAMAPTKDM4E | |
| SCHEMBL14574720 | 0.80 | BRAF (0.47) | BRAF | |
| SCHEMBL1492061 | 0.80 | BRAF (0.52) | BRAFTP53CYP2C9 | |
| SCHEMBL9930834 | 0.79 | BRAF (0.49) | BRAFTP53CYP2C9 | |
| SCHEMBL14574677 | 0.79 | BRAF (0.42) | BRAFTP53LMNAMAPT | |
| SCHEMBL14574876 | 0.79 | BRAF (0.36) | BRAFAPLNRTP53LMNAMAPT | |
| SCHEMBL9930556 | 0.79 | BRAF (0.48) | BRAFAPLNRTP53KDM4EMAPK1 | |
| SCHEMBL9930341 | 0.79 | BRAF (0.48) | BRAFAPLNRTP53CYP2C9 | |
| SCHEMBL9931391 | 0.79 | BRAF (0.42) | BRAFTP53LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157439-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885CYP3A4 2785/4885CYP2C19 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.